Identification and Characterization of Posttranslational Modification-Specific Binding Proteins in Vivo by Mammalian Tethered Catalysis

Total Page:16

File Type:pdf, Size:1020Kb

Identification and Characterization of Posttranslational Modification-Specific Binding Proteins in Vivo by Mammalian Tethered Catalysis Identification and characterization of posttranslational modification-specific binding proteins in vivo by mammalian tethered catalysis Tanya M. Spektor and Judd C. Rice1 Department of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033 Communicated by C. David Allis, The Rockefeller University, New York, NY, July 14, 2009 (received for review February 26, 2009) Increasing evidence indicates that an important consequence of To overcome some of the limitations of in vitro approaches, a protein posttranslational modification (PTM) is the creation of a high previously undescribed in vivo method called yeast tethered catal- affinity binding site for the selective interaction with a PTM-specific ysis was developed (1). Briefly, an expressed fusion protein con- binding protein (BP). This PTM-mediated interaction is typically re- taining a target peptide sequence was tethered to an enzyme quired for downstream signaling propagation and corresponding resulting in the constitutive PTM of the peptide and, thereby, biological responses. Because the vast majority of mammalian pro- served as the bait in yeast two-hybrid screens for putative PTMBPs. teins contain PTMs, there is an immediate need to discover and Although this technique was used successfully to identify yeast characterize previously undescribed PTMBPs. To this end, we devel- PTMBPs, the ability to detect PTMBPs in higher eukaryotes is oped and validated an innovative in vivo approach called mammalian constrained by the limitations of the yeast two-hybrid system. tethered catalysis (MTeC). By using methylated histones and methyl- By expanding on the principles of tethered catalysis, we have specific histone binding proteins as the proof-of-principle, we deter- developed and validated a previously undescribed in vivo approach mined that the new MTeC approach can compliment existing in vitro designed specifically for the discovery and characterization of binding methods, and can also provide unique in vivo insights into endogenous PTMBPs in mammalian cells, which we termed mam- PTM-dependent interactions. For example, we confirmed previous in malian tethered catalysis (MTeC). Methylated histones were cho- SCIENCES vitro findings that endogenous HP1 preferentially binds H3K9me3. sen as the proof-of-principle for MTeC, because increasing evi- However, in contrast to recent in vitro observations, MTeC revealed dence indicates that the major role of histone methylation is to bind APPLIED BIOLOGICAL that the tandem tudor domain-containing proteins, JMJD2A and distinct PTMBPs that, in turn, function to regulate a specific 53BP1, display no preferential H4K20 methyl-selectivity in vivo. Last, DNA-templated process such as transcription, replication, or repair by using MTeC in an unbiased manner to identify H3K9 methyl- (2). By testing various MTeC bait fusion proteins, we demonstrate specific PTMBPs, we determined that endogenous G9a binds meth- that this approach can be consistently used to predictably modify ylated H3K9 in vivo. Further use of MTeC to characterize this inter- MTeC bait fusion proteins in vivo. We also demonstrate that this action revealed that G9a selectively binds H3K9me1 in vivo, but not new technique can compliment existing in vitro binding assays, and H3K9me2, contrary to recent in vitro findings. Although this study importantly, can provide previously undescribed in vivo insights focused solely on methylated histones, we demonstrate how the into PTM-dependent interactions. Last, we show that MTeC was innovative MTeC approach could be used to identify and characterize used in an unbiased manner to identify an H3K9me1-specific any PTMBP that binds any PTM on any protein in vivo. binding protein in vivo. Collectively, our findings indicate that MTeC could be used as a new tool to identify and characterize ͉ ͉ ͉ ͉ 53BP1 G9a histone JMJD2A methylation PTMBPs that bind any PTM on any protein in vivo. ukaryotic cells have developed intricate and distinct cellular Results Esignaling cascades to translate particular intra or extracellular Principles and Implementation of MTeC. The overall goals of MTeC are stimuli into an appropriate biological response. These signaling to discover previously undescribed proteins, or validate those, that pathways rely heavily on enzymes that create specific posttransla- selectively bind to a target peptide sequence in vivo only when the tional modifications (PTMs) on certain proteins of the pathway. sequence possesses a specific PTM. As shown in Fig. 1A, MTeC These PTMs, themselves, are typically required for signal propa- begins with the creation of a bait expression plasmid that includes, gation and the desired biological response, indicating that the PTM in tandem, an affinity epitope tag followed by a peptide sequence of proteins is a central component of most normal cellular pro- containing the target amino acid to be modified and, finally, the grams. Recent advances in proteomics demonstrate that the vast catalytic domain of an enzyme known to modify the target residue majority of eukaryotic proteins are posttranslationally modified in of interest within the peptide sequence. The MTeC bait plasmid is vivo, presenting investigators with the formidable challenge of then introduced into the cells of choice where, once in the cell, the identifying the enzymes responsible for each PTM and, impor- catalytic domain of the expressed fusion protein is able to selectively tantly, determining the biological significance of each PTM on each posttranslationally modify the target residue within the peptide protein. sequence. The expressed MTeC fusion protein is then available to Increasing evidence indicates that one common outcome of interact in vivo with proteins that bind this particular modified protein PTM is the creation of a high affinity binding site for the peptide sequence. The cellular proteins bound to the modified selective interaction with a specific PTM-specific binding protein MTeC fusion protein can then be purified from cells by using (BP). The interaction between the PTMBP and the modified standard biochemical techniques, including fractionation of specific protein is often a critical step for downstream signaling and the biological response. Based on these observations, many have at- tempted to discover and characterize PTMBPs by using various Author contributions: J.C.R. designed research; T.M.S. performed research; T.M.S. and J.C.R. classic in vitro approaches. Although these methods are typically analyzed data; and T.M.S. and J.C.R. wrote the paper. amenable to high throughput screens, they are also subject to The authors declare no conflict of interest. numerous inherent limitations and because of these restrictions, 1To whom correspondence should be addressed. E-mail: [email protected]. have resulted in the identification of only a relatively small number This article contains supporting information online at www.pnas.org/cgi/content/full/ of bona fide PTMBPs. 0907799106/DCSupplemental. www.pnas.org͞cgi͞doi͞10.1073͞pnas.0907799106 PNAS Early Edition ͉ 1of6 Downloaded by guest on September 27, 2021 Fig. 1. Principles of MTeC. (A) An MTeC bait plasmid is composed of an affinity tag fused in tandem with a peptide sequence possessing an amino acid to be post- translationally modified in vivo followed by the catalytic domain of an enzyme known to modify the residue. (B) The MTeC bait plasmids are expressed in the cells of choice and, after the MTeC bait fusion protein is con- firmed to be properly modified in vivo, the PTMBPs are biochemically purified. After SDS/PAGE of the purified material, visible protein bands can be isolated and iden- tified by MS, or alternatively, complete sample mixtures can be submitted for protein identification. MTeC can also be used to verify and characterize PTM-dependent binding in vivo. subcellular compartments, affinity immunoprecipitation, and/or MTeC Bait Fusion Proteins Achieve Specific Degrees of H3K9 Methylation various other available chromatographic steps (Fig. 1B). Once this in Vivo. To test the ability of MTeC bait fusion proteins to acquire material is isolated, the purified proteins are analyzed by MS for the appropriate PTM in vivo, we capitalized on recent discoveries identification of the bound proteins. Importantly, the experiments and characterizations of enzymes that modify specific histone are performed in parallel with two critical controls. The first is an residues. In particular, we first focused on the well-described MTeC bait fusion protein lacking the catalytic domain of the methylation of histone H3 lysine 9 (H3K9) by the G9a methyl- enzyme, allowing subtraction of proteins that may bind both the transferase (3, 4). An MTeC bait plasmid containing a FLAG modified and unmodified peptide sequence. The second control is epitope and the first 44 aa of histone H3 were cloned upstream of an MTeC bait fusion protein where the modified target residue is the catalytic SET domain of the human G9a. Because we previously eliminated and, therefore, unavailable to be posttranslationally demonstrated that G9a is responsible for global dimethylation modified, allowing subtraction of interacting proteins that may bind (H3K9me2) in mammalian cells, and, in vitro, has also been shown another portion of the peptide sequence and/or the catalytic to cause trimethylation (H3K9me3), it was unclear which H3K9 domain of the tethered enzyme. Once the putative PTMBPs are methylated form would be observed in an H3-G9a WT MTeC bait identified,
Recommended publications
  • Covalent Flexible Peptide Docking in Rosetta
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.06.441297; this version posted May 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Covalent Flexible Peptide Docking in Rosetta Barr Tivon1,#, Ronen Gabizon1,#, Bente A. Somsen2, Peter J. Cossar2, Christian Ottmann2 , Nir London1,* 1 Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, 7610001, Israel 2 Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, P.O. Box 513, 5600MB Eindhoven, The Netherlands # equal contribution * Corresponding author: [email protected] Keywords: Covalent peptides; peptide docking; CovPepDock; FlexPepDock; 14-3-3; Electrophilic peptides; bioRxiv preprint doi: https://doi.org/10.1101/2021.05.06.441297; this version posted May 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Electrophilic peptides that form an irreversible covalent bond with their target have great potential for binding targets that have been previously considered undruggable. However, the discovery of such peptides remains a challenge. Here, we present CovPepDock, a computational pipeline for peptide docking that incorporates covalent binding between the peptide and a receptor cysteine. We applied CovPepDock retrospectively to a dataset of 115 disulfide-bound peptides and a dataset of 54 electrophilic peptides, for which it produced a top-five scoring, near-native model, in 89% and 100% of the cases, respectively.
    [Show full text]
  • A Global Review on Short Peptides: Frontiers and Perspectives †
    molecules Review A Global Review on Short Peptides: Frontiers and Perspectives † Vasso Apostolopoulos 1 , Joanna Bojarska 2,* , Tsun-Thai Chai 3 , Sherif Elnagdy 4 , Krzysztof Kaczmarek 5 , John Matsoukas 1,6,7, Roger New 8,9, Keykavous Parang 10 , Octavio Paredes Lopez 11 , Hamideh Parhiz 12, Conrad O. Perera 13, Monica Pickholz 14,15, Milan Remko 16, Michele Saviano 17, Mariusz Skwarczynski 18, Yefeng Tang 19, Wojciech M. Wolf 2,*, Taku Yoshiya 20 , Janusz Zabrocki 5, Piotr Zielenkiewicz 21,22 , Maha AlKhazindar 4 , Vanessa Barriga 1, Konstantinos Kelaidonis 6, Elham Mousavinezhad Sarasia 9 and Istvan Toth 18,23,24 1 Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia; [email protected] (V.A.); [email protected] (J.M.); [email protected] (V.B.) 2 Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland 3 Department of Chemical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Kampar 31900, Malaysia; [email protected] 4 Botany and Microbiology Department, Faculty of Science, Cairo University, Gamaa St., Giza 12613, Egypt; [email protected] (S.E.); [email protected] (M.A.) 5 Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland; [email protected] (K.K.); [email protected] (J.Z.) 6 NewDrug, Patras Science Park, 26500 Patras, Greece; [email protected] 7 Department of Physiology and Pharmacology,
    [Show full text]
  • Enhancer Priming by H3K4 Methylation Safeguards Germline Competence
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.07.192427; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Enhancer priming by H3K4 methylation safeguards germline competence 1* 1 1,2 Authors: Tore Bleckwehl ​ ,​ Kaitlin Schaaf ,​ Giuliano Crispatzu ,​ Patricia ​ ​ ​ ​ 1,3 1,4 5 5 Respuela ,​ Michaela Bartusel ,​ Laura Benson ,​ Stephen J. Clark ,​ Kristel M. ​ ​ ​ ​ 6 7 1,8 7,9 Dorighi ,​ Antonio Barral ,​ Magdalena Laugsch ,​ Miguel Manzanares ,​ Joanna ​ ​ ​ ​ 6,10,11 5,12,13 1,3,14* Wysocka ,​ Wolf Reik ,​ Álvaro Rada-Iglesias ​ ​ ​ ​ ​ ​ Affiliations: 1 Center for Molecular Medicine Cologne (CMMC), University of Cologne, Germany. 2 Department of Internal Medicine 2, University Hospital Cologne. 3 Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), CSIC/University of Cantabria, Spain. 4 Department of Biology, Massachusetts Institute of Technology, USA. 5 Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK. 6 Department of Chemical and Systems Biology, Stanford University School of Medicine, USA. 7 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain. 8 Institute of Human Genetics, Heidelberg University Hospital, Germany. 9 Centro de Biología Molecular Severo Ochoa (CBMSO), CSIC-UAM, Spain. 10 Department of Developmental Biology, Stanford University School of Medicine, USA. 11 Howard Hughes Medical Institute, Stanford University School of Medicine, USA. 12 Centre for Trophoblast Research, University of Cambridge, CB2 3EG, UK 13 Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
    [Show full text]
  • 1 Design and Production of Specifically and with High Affinity
    1 Design and Production of Specifically and with High Affinity Reacting Peptides (SHARP®-s) by Jan C Biro HOMULUS FOUNDATION, 612 S. Flower Str., #1220, 90017 CA, USA [email protected] www.janbiro.com 2 Abstract Background A partially random target selection method was developed to design and produce affinity reagents (target) to any protein query. It is based on the recent concept of Proteomic Code (for review see Biro, 2007 [1]) which suggests that significant number of amino acids in specifically interacting proteins are coded by partially complementary codons. It means that the 1st and 3rd residues of codons coding many co-locating amino acids are complementary but the 2nd may but not necessarily complementary: like 5’-AXG-3’/3’-CXT-5’ codon pair, where X is any nucleotide. Results A mixture of 45 residue long, reverse, partially complementary oligonucleotide sequences (target pool) were synthesized to selected epitopes of query mRNA sequences. The 2nd codon residues were randomized. The target oligonucleotide pool was inserted into vectors, expressed and the protein products were screened for affinity to the query in Bacterial Two-Hybrid System. The best clones were used for larger-scale protein syntheses and characterization. It was possible to design and produce specific and with high affinity reacting (Kd: ~100 nM) oligopeptide reagents to GAL4 query oligopeptides. Conclusions Second codon residue randomization is a promising method to design and produce affinity peptides to any protein sequences. The method has the potential to be a rapid, inexpensive, high throughput, non-immunoglobulin based alternative to recent in vivo antibody generating procedures.
    [Show full text]
  • Dimethylation of Histone 3 Lysine 9 Is Sensitive to the Epileptic Activity
    1368 MOLECULAR MEDICINE REPORTS 17: 1368-1374, 2018 Dimethylation of Histone 3 Lysine 9 is sensitive to the epileptic activity, and affects the transcriptional regulation of the potassium channel Kcnj10 gene in epileptic rats SHAO-PING ZHANG1,2*, MAN ZHANG1*, HONG TAO1, YAN LUO1, TAO HE3, CHUN-HUI WANG3, XIAO-CHENG LI3, LING CHEN1,3, LIN-NA ZHANG1, TAO SUN2 and QI-KUAN HU1-3 1Department of Physiology; 2Ningxia Key Laboratory of Cerebrocranial Diseases, Incubation Base of National Key Laboratory, Ningxia Medical University; 3General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China Received February 18, 2017; Accepted September 13, 2017 DOI: 10.3892/mmr.2017.7942 Abstract. Potassium channels can be affected by epileptic G9a by 2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6,7-di- seizures and serve a crucial role in the pathophysiology of methoxy-N-(1-(phenyl-methyl)-4-piperidinyl)-4-quinazolinamine epilepsy. Dimethylation of histone 3 lysine 9 (H3K9me2) and tri-hydrochloride hydrate (bix01294) resulted in upregulation its enzyme euchromatic histone-lysine N-methyltransferase 2 of the expression of Kir4.1 proteins. The present study demon- (G9a) are the major epigenetic modulators and are associated strated that H3K9me2 and G9a are sensitive to epileptic seizure with gene silencing. Insight into whether H3K9me2 and G9a activity during the acute phase of epilepsy and can affect the can respond to epileptic seizures and regulate expression of transcriptional regulation of the Kcnj10 channel. genes encoding potassium channels is the main purpose of the present study. A total of 16 subtypes of potassium channel Introduction genes in pilocarpine-modelled epileptic rats were screened by reverse transcription-quantitative polymerase chain reac- Epilepsies are disorders of neuronal excitability, characterized tion, and it was determined that the expression ATP-sensitive by spontaneous and recurrent seizures.
    [Show full text]
  • Deep Time-Resolved Proteomic and Phosphoproteomic Profiling Of
    Deep time-resolved proteomic and phosphoproteomic profiling of cigarette smoke-induced chronic obstructive pulmonary disease David Skerrett-Byrne BSc Biochem & Mol Bio (Hons)(UCD) MSc Biotech (UU) 25th March 2019 Supervisors: Professor Phil Hansbro, Dr. Matt Dun, Laureate Professor Rodney Scott, Professor Peter Wark, Professor Darryl Knight, Laureate Professor Paul Foster Discipline of Immunology and Microbiology and Priority Research Centre for Healthy Lungs School of Biomedical Science and Pharmacy Faculty of Health and Medicine University of Newcastle and Hunter Medical Research Institute Newcastle, NSW, Australia Submitted in fulfilment of the requirements for the award of a Doctor of Philosophy Declaration Statement of Originality I hereby certify that the work embodied in the thesis is my own work, conducted under normal supervision. The thesis contains no material which has been accepted, or is being examined, for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made. I give consent to the final version of my thesis being made available worldwide when deposited in the University’s Digital Repository, subject to the provisions of the Copyright Act 1968 and any approved embargo. ________________________ David Skerrett-Byrne 25/03/2019 Acknowledgment of Authorship I hereby certify that the work embodied in this thesis contains scholarly work of which I am a joint author. I have included as part of the thesis a written declaration endorsed in writing by my supervisor, attesting to my contribution to the joint scholarly work.
    [Show full text]
  • Centenary Award and Sir Frederick Gowland Hopkins Memorial Lecture
    Centenary Award and Sir Frederick Gowland Hopkins Memorial Lecture Centenary Award and Sir Frederick Gowland Hopkins Memorial Lecture Seeing the invisible by paramagnetic and diamagnetic NMR G. Marius Clore*1 *Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, U.S.A. scale interdomain motions involved in ligand binding, and to the interaction of monomeric amyloid β-peptide with the surface of amyloid protofibrils and the internal cavity surface of Centenary Award and Sir Frederick the chaperonin GroEL. Gowland Hopkins Memorial Lecture Delivered at the MRC Laboratory of Molecular Biology, Cambridge, on Introduction 13 December 2012 Proteins and their complexes are not static but dynamic and Marius Clore are best described as an ensemble of states. The major species is located at the minimum of the free energy landscape and represents the species that has been studied with so much Abstract success by conventional structural and biophysical tech- niques, including crystallography and NMR. But the static Sparsely populated transient states of proteins and their picture revealed by these studies does not describe the complexes play an important role in many biological processes complete picture. In addition to the major species, there exist including protein–protein and protein–DNA recognition, al- highly transient sparsely populated states that arise from rare lostery, conformational selection, induced fit and self-assembly. excursions between the minimum free energy configuration These states are difficult to study as their low population and other local minima of the free energy landscape [1]. Given and transient nature makes them effectively invisible to that the populations of such sparsely populated states are so conventional structural and biophysical techniques.
    [Show full text]
  • Caenorhabditis Elegans Deficient in DOT-1.1 Exhibit Increases in H3k9me2 at Enhancer and Certain Rnai-Regulated Regions
    cells Article Caenorhabditis elegans Deficient in DOT-1.1 Exhibit Increases in H3K9me2 at Enhancer and Certain RNAi-Regulated Regions Ruben Esse y and Alla Grishok * Department of Biochemistry, BU Genome Science Institute, Boston University School of Medicine, Boston, MA 02118, USA; [email protected] * Correspondence: [email protected] Present address: Department of Medical and Molecular Genetics, King’s College London, y London SE1 9RT, UK. Received: 15 May 2020; Accepted: 29 July 2020; Published: 6 August 2020 Abstract: The methylation of histone H3 at lysine 79 is a feature of open chromatin. It is deposited by the conserved histone methyltransferase DOT1. Recently, DOT1 localization and H3K79 methylation (H3K79me) have been correlated with enhancers in C. elegans and mammalian cells. Since earlier research implicated H3K79me in preventing heterochromatin formation both in yeast and leukemic cells, we sought to inquire whether a H3K79me deficiency would lead to higher levels of heterochromatic histone modifications, specifically H3K9me2, at developmental enhancers in C. elegans. Therefore, we used H3K9me2 ChIP-seq to compare its abundance in control and dot-1.1 loss-of-function mutant worms, as well as in rde-4; dot-1.1 and rde-1; dot-1.1 double mutants. The rde-1 and rde-4 genes are components of the RNAi pathway in C. elegans, and RNAi is known to initiate H3K9 methylation in many organisms, including C. elegans. We have previously shown that dot-1.1( ) − lethality is rescued by rde-1 and rde-4 loss-of-function. Here we found that H3K9me2 was elevated in enhancer, but not promoter, regions bound by the DOT-1.1/ZFP-1 complex in dot-1.1( ) worms.
    [Show full text]
  • G9a Selectively Represses a Class of Late-Replicating Genes at the Nuclear Periphery
    G9a selectively represses a class of late-replicating genes at the nuclear periphery Tomoki Yokochia,1, Kristina Poducha, Tyrone Rybaa, Junjie Lua, Ichiro Hiratania, Makoto Tachibanab, Yoichi Shinkaib, and David M. Gilberta,2 aDepartment of Biological Science, Florida State University, Tallahassee, FL 32306; and bExperimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan Edited by Mark T. Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved September 25, 2009 (received for review June 4, 2009) We have investigated the role of the histone methyltransferase G9a ery and that G9a-null ESCs are selectively depleted of the in the establishment of silent nuclear compartments. Following con- H3K9me2 localized at the periphery (13). Chromatin at the nuclear ditional knockout of the G9a methyltransferase in mouse ESCs, 167 periphery also is replicated late during S-phase, and differentiation genes were significantly up-regulated, and no genes were strongly of ESCs leads to changes in the replication timing of large chro- down-regulated. A partially overlapping set of 119 genes were matin domains, accompanied by the movement of those domains up-regulated after differentiation of G9a-depleted cells to neural toward or away from the nuclear periphery and the respective precursors. Promoters of these G9a-repressed genes were AT rich and silencing or activation of genes within those domains (14). To- H3K9me2 enriched but H3K4me3 depleted and were not highly DNA gether, these results suggested the possibility that G9a may help methylated. Representative genes were found to be close to the establish compartments of facultative heterochromatin at the nu- nuclear periphery, which was significantly enriched for G9a-depen- clear periphery.
    [Show full text]
  • Catalytic Inhibition of H3k9me2 Writers Disturbs Epigenetic Marks
    www.nature.com/scientificreports OPEN Catalytic inhibition of H3K9me2 writers disturbs epigenetic marks during bovine nuclear reprogramming Rafael Vilar Sampaio 1,3,4*, Juliano Rodrigues Sangalli1,4, Tiago Henrique Camara De Bem 1, Dewison Ricardo Ambrizi1, Maite del Collado 1, Alessandra Bridi 1, Ana Clara Faquineli Cavalcante Mendes de Ávila1, Carolina Habermann Macabelli 2, Lilian de Jesus Oliveira1, Juliano Coelho da Silveira 1, Marcos Roberto Chiaratti 2, Felipe Perecin 1, Fabiana Fernandes Bressan1, Lawrence Charles Smith3, Pablo J Ross 4 & Flávio Vieira Meirelles1* Orchestrated events, including extensive changes in epigenetic marks, allow a somatic nucleus to become totipotent after transfer into an oocyte, a process termed nuclear reprogramming. Recently, several strategies have been applied in order to improve reprogramming efciency, mainly focused on removing repressive epigenetic marks such as histone methylation from the somatic nucleus. Herein we used the specifc and non-toxic chemical probe UNC0638 to inhibit the catalytic activity of the histone methyltransferases EHMT1 and EHMT2. Either the donor cell (before reconstruction) or the early embryo was exposed to the probe to assess its efect on developmental rates and epigenetic marks. First, we showed that the treatment of bovine fbroblasts with UNC0638 did mitigate the levels of H3K9me2. Moreover, H3K9me2 levels were decreased in cloned embryos regardless of treating either donor cells or early embryos with UNC0638. Additional epigenetic marks such as H3K9me3, 5mC, and 5hmC were also afected by the UNC0638 treatment. Therefore, the use of UNC0638 did diminish the levels of H3K9me2 and H3K9me3 in SCNT-derived blastocysts, but this was unable to improve their preimplantation development.
    [Show full text]
  • Abo1 Is Required for the H3k9me2 to H3k9me3 Transition in Heterochromatin Wenbo Dong1, Eriko Oya1, Yasaman Zahedi1, Punit Prasad 1,2, J
    www.nature.com/scientificreports OPEN Abo1 is required for the H3K9me2 to H3K9me3 transition in heterochromatin Wenbo Dong1, Eriko Oya1, Yasaman Zahedi1, Punit Prasad 1,2, J. Peter Svensson 1, Andreas Lennartsson1, Karl Ekwall1 & Mickaël Durand-Dubief 1* Heterochromatin regulation is critical for genomic stability. Diferent H3K9 methylation states have been discovered, with distinct roles in heterochromatin formation and silencing. However, how the transition from H3K9me2 to H3K9me3 is controlled is still unclear. Here, we investigate the role of the conserved bromodomain AAA-ATPase, Abo1, involved in maintaining global nucleosome organisation in fssion yeast. We identifed several key factors involved in heterochromatin silencing that interact genetically with Abo1: histone deacetylase Clr3, H3K9 methyltransferase Clr4, and HP1 homolog Swi6. Cells lacking Abo1 cultivated at 30 °C exhibit an imbalance of H3K9me2 and H3K9me3 in heterochromatin. In abo1∆ cells, the centromeric constitutive heterochromatin has increased H3K9me2 but decreased H3K9me3 levels compared to wild-type. In contrast, facultative heterochromatin regions exhibit reduced H3K9me2 and H3K9me3 levels in abo1∆. Genome-wide analysis showed that abo1∆ cells have silencing defects in both the centromeres and subtelomeres, but not in a subset of heterochromatin islands in our condition. Thus, our work uncovers a role of Abo1 in stabilising directly or indirectly Clr4 recruitment to allow the H3K9me2 to H3K9me3 transition in heterochromatin. In eukaryotic cells, the regions of the chromatin that contain active genes are termed euchromatin, and these regions condense in mitosis to allow for chromosome segregation and decondense in interphase to allow for gene transcription1. Te chromatin regions that remain condensed throughout the cell cycle are defned as het- erochromatin regions and are transcriptionally repressed2,3.
    [Show full text]
  • Uncovering the Modified Immunopeptidome Reveals Insights Into Principles of PTM- Driven Antigenicity
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.10.438991; this version posted April 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Uncovering the modified immunopeptidome reveals insights into principles of PTM- driven antigenicity Assaf Kacen 1*, Aaron Javitt 1*, Matthias P. Kramer 1*, David Morgenstern 2, Tomer Tsaban 4, Adam Solomon1 ,Guo Ci Teo 3, Felipe da Veiga Leprevost 3, Eilon Barnea 5, Fengchao Yu3, Arie Admon 5, Lea Eisenbach1, Gal Cafri 7, Ora Schueler-Furman 4, Yishai Levin 2, Alexey I. Nesvizhskii 3,6, Yifat Merbl1$ 1. Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. 2. De Botton Institute for Protein Profiling, Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel. 3. Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA. 4. Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University, Jerusalem, Israel. 5. Faculty of Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel. 6. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA. 7. Sheba Medical Center, Ramat Gan, Israel *Equal contributions $ Correspondence: [email protected] Abstract Antigen processing and presentation are critical for modulating tumor-host interactions. While post-translational modifications (PTMs) can alter the binding and recognition of antigens, their identification remains challenging.
    [Show full text]